Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice

Blood

Volumn 97, Issue 12, 2001, Pages 3746-3754

  Grote, Deanna ^a,b   Russell, Stephen J ^a,b   Cornu, Tatjana I ^a,b   Cattaneo, Roberta ^a,b   Vile, Richard ^a,b   Poland, Gregory A ^a,b   Fielding, Adele K ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; MEASLES VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DNA MODIFICATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REPORTER GENE; SCID MOUSE; TUMOR XENOGRAFT; VIRUS INACTIVATION; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0035877990     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3746     Document Type: Article

References (37)

1. Smith R, Huebner J, Rowe W, Schatten W, Thomas L. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211-1218.
2. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
3. Heise C, Kirn D. Replication-selective adenoviruses as oncolytic agents. J Clin Invest. 2000;105:847-851.
4. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332-1334.
5. Mineta T, Rabbkin S, Yazaki T, Hunter W, Martuza R. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1995;1:938-943.
6. Martuza R. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest. 2000;105:841-846.
7. Stojdl D, Lichty B, Knowles S, et al. Exploiting tumor-specific defect in the interferon pathway with a previously unknown oncolytic virus. Nature Med. 2000;6:821-825.
8. Khuri F, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 2000;6:879-885.
9. Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34:1907-1928.
10. Lorence RM, Rood PA, Kelley KW. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst. 1988;80:1305-1312.
11. Lorence RM, Reichard KW, Katubig BB, et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 1994;86:1228-1233.
12. Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992;52:448-453.
13. Enders J, Peebles T. Propagation in tissue culture of cytopathic agents from patients with measles. Proc Soc Exp Biol Med. 1954;86:277-286.
14. Warthin A. Occurrence of numerous large giant cells in tonsils and pharyngeal mucosa in the prodromal stage of measles. Arch Pathol. 1931;11:864-874.
15. Fielding AK, Chapel-Fernandes S, Chadwick MP, Bullough FJ, Cosset FL, Russell SJ. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther. 2000;11:817-826.
16. Bateman A, Bullough F, Murphy S, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 2000;60:1492-1497.
17. Diaz RM, Bateman A, Emiliusen L, et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther. 2000;7:1656-1663.
18. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin's disease after measles. Lancet. 1981;1:1112.
19. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971;2:105-106.
20. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75:295-305.
21. Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67:6025-6032.
22. Norrby E, Oxman MN. Measles virus. In: Fields BN, Knipe DM, et al, eds. Virology. New York, NY: Raven Press; 1990:1013-1044.
23. Spearman C. The method of right and wrong cases (constant stimuli) without Gauss's formula. Br J Psychol. 1908;2:227-242.
24. Cornu T. Use of Measles Virus as a Vector: Stable Expression of a Supplementary Large Transcription Unit or Additional Foreign Viral Glycoproteins. Zurich, Switzerland: University of Zurich; 1997.
25. Neumeister C, Nanan R, Cornu TI, et al. Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway. J Gen Virol. 2001;82:441-447.
26. Mrkic B, Pavlovic J, Rulicke T, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol. 1998;72:7420-7427.
27. Schlereth B, Rose JK, Buonocore L, ter Meulen V, Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. 2000;74:4652-4657.
28. Pulvertaft RJV. Cytology of Burkitt's tumour (African lymphoma). Lancet. 1964;1:238-240.
29. Kluin-Nelemans HC, Limpens J, Meerabux J, et al. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia. 1991;5:221-224.
30. Heise CC, Williams A, Olesch J, Kirn DH. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 1999;6:499-504.
31. Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol. 2000;74:9928-9936.
32. Hammond A, Plemper R, Zhang J, Schneider U, Russell S, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol. 2000;75:2087-2096.
33. Menoret A, Parry Y, Burg C, Le Pendu J. Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas. J Immunol. 1995;155:740-747.
34. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG, Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med. 1998;4:581-587.
35. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 1998;8:657-665.
36. Matzinger P. An innate sense of danger. Semin Immunol. 1998;10:399-415.
37. Wells AD, Malkovsky M. Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today. 2000;21:129-132.